Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CMND Clearmind Medicine, Inc.

Market Closed 07-02 16:00:00 EDT

2.36

+0.06

+2.61%

盘后2.30

-0.06-2.54%

19:57 EDT

High2.42	Low2.28	Vol66.62K
Open2.28	D1 Closing2.30	Amplitude6.00%
Mkt Cap3.51M	Tradable Cap3.50M	Total Shares1.49M
T/O156.70K	T/O Rate4.49%	Tradable Shares1.48M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CMND","market":"US","secType":"STK","nameCN":"Clearmind Medicine, Inc.","latestPrice":2.36,"timestamp":1783022400000,"preClose":2.3,"halted":0,"volume":66622,"hourTrading":{"tag":"盘后","latestPrice":2.3,"preClose":2.36,"latestTime":"19:57 EDT","volume":1649,"amount":3827.1607,"timestamp":1783036678048,"change":-0.06,"changeRate":-0.025424,"amplitude":0.025424},"delay":0,"changeRate":0.026086956521739157,"floatShares":1484199,"shares":1485551,"eps":-175.92,"marketStatus":"Market Closed","change":0.06,"latestTime":"07-02 16:00:00 EDT","open":2.28,"high":2.418,"low":2.28,"amount":156695.69016640002,"amplitude":0.06,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-175.92,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1783324800000},"marketStatusCode":7,"adr":0,"listingDate":1668142800000,"exchange":"NASDAQ","adjPreClose":2.3,"preHourTrading":{"tag":"盘前","latestPrice":2.33,"preClose":2.3,"latestTime":"09:22 EDT","volume":4899,"amount":11463.077998800001,"timestamp":1782998520811,"change":0.03,"changeRate":0.013043,"amplitude":0.09587},"postHourTrading":{"tag":"盘后","latestPrice":2.3,"preClose":2.36,"latestTime":"19:57 EDT","volume":1649,"amount":3827.1607,"timestamp":1783036678048,"change":-0.06,"changeRate":-0.025424,"amplitude":0.025424},"volumeRatio":0.06260051771316714},"requestUrl":"/m/hq/s/CMND/tweets","defaultTab":"tweets","newsList":[{"id":"2647795853","title":"Clearmind Medicine Wins New US Patent for Binge Behavior Regulators","url":"https://stock-news.laohu8.com/highlight/detail?id=2647795853","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647795853?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:55","pubTimestamp":1782734113,"startTime":"0","endTime":"0","summary":"Clearmind Medicine wins new US patent for binge behavior regulatorsClearmind Medicine received a newly granted U.S. patent for “Binge Behavior Regulators,” U.S. Patent No. 12,357,590.The patent expand","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL6Lkzx3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","CMND","BK4588","BK4007","SG9999014013.SGD","SG9999014039.USD","NDAQ","SG9999014021.USD","LU2210149790.SGD","LU2095319765.USD","SG9999014005.SGD","IE00BN0W2T93.GBP","IE00BKPKM429.USD","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","LU2210150020.SGD","BK4585","BK4112","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645602442","title":"Clearmind completes Part A dosing in Phase I/II CMND-100 trial for alcohol use disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2645602442","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645602442?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:07","pubTimestamp":1782130036,"startTime":"0","endTime":"0","summary":"Clearmind Medicine completed Part A treatment in its FDA-regulated Phase I/II trial of CMND-100 for Alcohol Use Disorder.Results have not been presented; the dataset is under review.All 24 participants across four cohorts finished dosing under the study protocol.Next-stage initiation is planned if the review remains favorable, marking a potential advance in its AUD development program.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL9kp5TZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","SG9999014039.USD","BK4112","CMND","LU0314104364.USD","IE00BN0W2V16.EUR","IE00BKPKM429.USD","SG9999014021.USD","LU2210149790.SGD","LU2210150020.SGD","LU2095319765.USD","BK4585","BK4007","BK4588","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","NDAQ","SG9999014005.SGD","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645102441","title":"Clearmind Medicine - to Initiate Next Stage of Clinical Program for Alcohol Use Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2645102441","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645102441?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:07","pubTimestamp":1782130020,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUA2FQJGV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645024465","title":"Clearmind Medicine Reaches Major Milestone, Completing Part a Treatment in FDA‑Regulated Phase I/Ii Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2645024465","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645024465?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:07","pubTimestamp":1782130020,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUA2FQJGV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644397420","title":"HRT Financial LP disposes of $73,191 in Clearmind Medicine common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2644397420","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644397420?lang=en_us&edition=fundamental","pubTime":"2026-06-19 05:06","pubTimestamp":1781816779,"startTime":"0","endTime":"0","summary":"HRT Financial LP cut its stake in Clearmind Medicine, selling 22,139 Class A shares on June 16.The shares were sold at USD 3.31 each.HRT Financial LP reported 81,353 Class A shares beneficially owned following the sale.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL1yFnJx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"HRT Financial LP disposes of $73,191 in Clearmind Medicine common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644330081","title":"Psychedelic: Clearmind completes Part A dosing for Phase I/II CMND-100 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2644330081","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644330081?lang=en_us&edition=fundamental","pubTime":"2026-06-18 22:00","pubTimestamp":1781791242,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a dosing completion, psilocybin p...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/psychedelic-clearmind-completes-part-a-dosing-for-phase-i-ii-cmnd-100-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/psychedelic-clearmind-completes-part-a-dosing-for-phase-i-ii-cmnd-100-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644088020","title":"Clearmind Medicine wins US patent for MEAI-based binge behavior regulators","url":"https://stock-news.laohu8.com/highlight/detail?id=2644088020","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644088020?lang=en_us&edition=fundamental","pubTime":"2026-06-18 19:55","pubTimestamp":1781783717,"startTime":"0","endTime":"0","summary":"Clearmind Medicine won a U.S. patent covering compositions and methods using MEAI salts to regulate binge behaviors.The USPTO issued Patent No. 12,350,242, titled “Binge Behavior Regulators.”Scope includes potential use in binge-related disorders, including alcohol use disorder.Clearmind said the grant lifts its portfolio to 32 issued patents.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDLcbfqj7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IE00B64PRP62.GBP","SG9999014005.SGD","IE00BGHQF748.EUR","BK4112","LU2210149790.SGD","SG9999014013.SGD","LU0314104364.USD","NDAQ","IE00BN0W2W23.USD","IE00BKPKM429.USD","SG9999014039.USD","LU2210150020.SGD","IE00BN0W2T93.GBP","SG9999014021.USD","CMND","LU2095319765.USD","IE00B3QW5Z07.USD","BK4588","BK4585","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644721750","title":"HRT Financial LP sells 3,183 Clearmind Medicine common shares for $10,567.56","url":"https://stock-news.laohu8.com/highlight/detail?id=2644721750","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644721750?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:43","pubTimestamp":1781729014,"startTime":"0","endTime":"0","summary":"HRT Financial, a 10% owner of Clearmind Medicine, sold 3,183 common shares on June 15, 2026 at $3.32.Stake fell to 103,492 shares following the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL6qYvPL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"HRT Financial LP sells 3,183 Clearmind Medicine common shares for $10,567.56","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643750188","title":"HRT Financial LP disposes of 2,102 Clearmind Medicine common shares worth $7,062.72","url":"https://stock-news.laohu8.com/highlight/detail?id=2643750188","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643750188?lang=en_us&edition=fundamental","pubTime":"2026-06-16 21:19","pubTimestamp":1781615996,"startTime":"0","endTime":"0","summary":"HRT Financial, a 10% owner of Clearmind Medicine, sold 2,102 common shares on June 12, 2026 at USD 3.36.Stake fell to 106,675 shares following the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 16, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL7SgdYD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"HRT Financial LP disposes of 2,102 Clearmind Medicine common shares worth $7,062.72","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643076752","title":"BRIEF-Clearmind Medicine Completes Dosing For Part A Of Its Of FDA-Regulated Phase I/Ii Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2643076752","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643076752?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:39","pubTimestamp":1781613550,"startTime":"0","endTime":"0","summary":"BRIEF-Clearmind Medicine Completes Dosing For Part A Of Its Of FDA-Regulated Phase I/Ii Clinical TrialJune 16 (Reuters) - Clearmind Medicine Inc CMND.O:CLEARMIND MEDICINE COMPLETES DOSING FOR PART A O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nTUA2TWKSX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643754138","title":"Clearmind Medicine Completes Dosing in First 4 Cohorts of Phase I/II Alcohol Use Disorder Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2643754138","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643754138?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:55","pubTimestamp":1781610950,"startTime":"0","endTime":"0","summary":"Clearmind Medicine (CMND) said Tuesday it has completed dosing for all 24 participants in cohorts 1 through 4 of part A of its ongoing phase 1/II trial evaluating its experimental drug, CMND-100, for ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643785751","title":"Clearmind completes Part A dosing in Phase I/II CMND-100 trial for alcohol use disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2643785751","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643785751?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:32","pubTimestamp":1781609535,"startTime":"0","endTime":"0","summary":"Clearmind Medicine completed dosing for Part A of its FDA-regulated Phase I/II trial of CMND-100 in Alcohol Use Disorder.Interim results from the first three cohorts were already presented, indicating a favorable safety profile without detailing efficacy metrics.The study is a multicenter, randomized, double-blind, placebo-controlled trial run under an FDA IND.Part A treated 24 healthy participants across four escalating-dose cohorts, supporting progression to later-stage trial activities.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL3G2ltg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4112","LU0314104364.USD","LU2210150020.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","CMND","SG9999014039.USD","IE00BN0W2T93.GBP","SG9999014021.USD","BK4588","BK4585","NDAQ","LU2095319765.USD","IE00BGHQF748.EUR","SG9999014013.SGD","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00BKPKM429.USD","BK4007","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643227751","title":"Clearmind Medicine Completes Dosing for Part a of Its of FDA-Regulated Phase I/Ii Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2643227751","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643227751?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:32","pubTimestamp":1781609520,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nTUA2TWKSX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643567218","title":"Clearmind Medicine says HRT Financial files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2643567218","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643567218?lang=en_us&edition=fundamental","pubTime":"2026-06-13 04:20","pubTimestamp":1781295630,"startTime":"0","endTime":"0","summary":"HRT Financial filed a Form 3 disclosing a 10% stake in Clearmind Medicine as of June 10, 2026.The filing shows direct ownership of 101,951 shares of Common Stock.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 12, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDL3XJ867:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641574480","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 10:26 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2641574480","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641574480?lang=en_us&edition=fundamental","pubTime":"2026-06-08 22:26","pubTimestamp":1780928780,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 10:26 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nAQN2M2JSL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641117103","title":"Clearmind Medicine spotlights new CMND-100 alcohol use disorder trial data in June 10 webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2641117103","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641117103?lang=en_us&edition=fundamental","pubTime":"2026-06-05 19:32","pubTimestamp":1780659144,"startTime":"0","endTime":"0","summary":"Clearmind Medicine scheduled a June 10, 2026 webinar to present new insights from its ongoing Phase I/IIa trial of CMND-100 for alcohol use disorder.Trial data will be discussed in the future during a live investigator Q&A with researchers from Yale and Johns Hopkins.Focus is an update on clinical progress for an oral, non-hallucinogenic MEAI-based candidate, not a product launch or commercial rollout.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nNDLMX8Tx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2210150020.SGD","LU2210149790.SGD","LU2095319765.USD","CMND","BK4112","BK4007","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","SG9999014005.SGD","NDAQ","IE00BGHQF748.EUR","LU0314104364.USD","SG9999014039.USD","SG9999014013.SGD","SG9999014021.USD","BK4588","IE00BKPKM429.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641171791","title":"Clearmind Medicine to Feature New Insights From Cmnd-100 Psychedelic Clinical Trial on “Inside Meai” Webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2641171791","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641171791?lang=en_us&edition=fundamental","pubTime":"2026-06-05 19:32","pubTimestamp":1780659120,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nTUA71DG7J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641002117","title":"Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2641002117","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641002117?lang=en_us&edition=fundamental","pubTime":"2026-06-05 19:32","pubTimestamp":1780659120,"startTime":"0","endTime":"0","summary":"Yale and Johns Hopkins Researchers to Present Early Findings on MEAI Next Week in Live WebinarRegister now for free and joinon June 10, 2026 Vancouver, Canada, June  05, 2026  (GLOBE NEWSWIRE) -- Clea","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/05/3307314/0/en/Clearmind-Medicine-to-Feature-New-Insights-from-CMND-100-Psychedelic-Clinical-Trial-on-Inside-MEAI-Webinar.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640964670","title":"Clearmind Medicine to sell $1.5 million in convertible promissory notes at 90% of face value","url":"https://stock-news.laohu8.com/highlight/detail?id=2640964670","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640964670?lang=en_us&edition=fundamental","pubTime":"2026-06-02 04:12","pubTimestamp":1780344722,"startTime":"0","endTime":"0","summary":"Clearmind Medicine entered a deal to sell $1.5 million of convertible promissory notes to CLA Investors, with closing expected on June 1, 2026.Cash proceeds set at $1.35 million, reflecting a 90% purchase price to principal.The issuance sits within an amended facility to issue up to $10 million of convertible promissory notes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 01, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL6jSmKF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640968712","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 11:27 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2640968712","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640968712?lang=en_us&edition=fundamental","pubTime":"2026-06-01 23:27","pubTimestamp":1780327666,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 11:27 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nAQN2M1J84:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.clearmindmedicine.com","stockEarnings":[{"period":"1week","weight":-0.0522},{"period":"1month","weight":-0.1918},{"period":"3month","weight":-0.7815},{"period":"6month","weight":-0.8814},{"period":"1year","weight":-0.9935},{"period":"ytd","weight":-0.8696}],"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":-0.0195},{"period":"3month","weight":0.1356},{"period":"6month","weight":0.0902},{"period":"1year","weight":0.2004},{"period":"ytd","weight":0.0922}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company has a collaboration with Clearmind Medicine Inc. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.040615},{"month":2,"riseRate":0.25,"avgChangeRate":-0.154491},{"month":3,"riseRate":0,"avgChangeRate":-0.280646},{"month":4,"riseRate":0.25,"avgChangeRate":-0.205941},{"month":5,"riseRate":0.25,"avgChangeRate":-0.137133},{"month":6,"riseRate":0.25,"avgChangeRate":-0.036058},{"month":7,"riseRate":0.5,"avgChangeRate":0.024562},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.088917},{"month":9,"riseRate":0,"avgChangeRate":-0.22938},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.107561},{"month":11,"riseRate":0,"avgChangeRate":-0.304445},{"month":12,"riseRate":0.25,"avgChangeRate":-0.256594}],"exchange":"NASDAQ","name":"Clearmind Medicine, Inc.","nameEN":"Clearmind Medicine, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.0","shortVersion":"4.45.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Clearmind Medicine, Inc.(CMND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Clearmind Medicine, Inc.,CMND,Clearmind Medicine, Inc.股票,Clearmind Medicine, Inc.股票老虎,Clearmind Medicine, Inc.股票老虎国际,Clearmind Medicine, Inc.行情,Clearmind Medicine, Inc.股票行情,Clearmind Medicine, Inc.股价,Clearmind Medicine, Inc.股市,Clearmind Medicine, Inc.股票价格,Clearmind Medicine, Inc.股票交易,Clearmind Medicine, Inc.股票购买,Clearmind Medicine, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Clearmind Medicine, Inc.(CMND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction